Philips expands R&D deal with Theseus

Jun 22, 2004

Philips Medical Systems of Andover, MA, has expanded its research collaboration with Theseus Imaging regarding a tumor imaging radiopharmaceutical being developed by Theseus, a subsidiary of North American Scientific of Chatsworth, CA.

Under the terms of the deal, Theseus will send Philips imaging data from clinical studies of its Tc-99m-hynic annexin molecular imaging agent. Philips' Molecular Imaging business unit will process the data using ADAC image enhancement software, which the companies hope will speed the transition of the product from preclinical trials to clinical trials and product development.

Tc-99m-hynic annexin is in phase II clinical studies for imaging cell death in vivo to provide noninvasive molecular characterization of tumors, and early evaluation of tumor response to anti-cancer treatment. Other clinical studies have suggested that the agent could be used to evaluate unstable atherosclerotic plaque in the carotid arteries and areas of nerve cell damage in stroke.

By AuntMinnie.com staff writers
June 23, 2004
Related Reading

Philips adds to molecular imaging line, June 22, 2004

Philips inks research deal with University of Chicago, May 20, 2004

Profits rise at Philips Medical, April 22, 2004

NAS back on track with Hynic-Annexin V, June 13, 2004

Theseus in co-development deal with NCI, February 18, 2003

Theseus withdraws IND application, January 21, 2003

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$